The usage of dosimetry of small fields in radiotherapy to measure radiation dose is difficult because of high-dose gradients, lateral electronic disequilibrium, and detector volume effects. In this study, three dosimeters namely, Markus, Semiflex 3D, and Diode E were tested using the Elekta-accelerator electron beams. The electron beam parameters, penumbra, and output factor were determined using these dosimeters for each field size and energy. According to the results, Diode E and Advanced Markus exhibited the greatest difference in Rq among the electron beam parameters. Furthermore, the greatest difference in penumbra was observed between Diode E and Advanced Markus for the field size of 3 cm at 10 MeV. In terms of output factor, three dosimeters exhibited the greatest difference between Diode E and Advanced Markus for the field size of 3 cm at 10 MeV. The findings indicate that the Semiflex 3D can be regarded as an appropriate dosimeter for electron small-field dosimetry.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12194-020-00577-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Kinetics of recovery and normalization of running biomechanics following aerobic-based exercise-induced muscle damage in recreational male runners.
J Sci Med Sport
January 2025
Department of Health Promotion, School of Public Health, Faculty of Medical and Health Sciences, Sylvan Adams Sports Institute, Tel-Aviv University, Israel. Electronic address:
Objectives: The study aimed to examine the effects of exercise-induced muscle damage on running kinetics.
Design: Twenty-six adult recreational male runners performed 60 min of downhill running (-10 %) at 65 % of maximal heart rate. Running gait changes, systemic and localized muscle damage markers were assessed pre - and post-exercise induced muscle damage protocol.
Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy.
Eur J Nucl Med Mol Imaging
January 2025
Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt Am Main, Frankfurt, Germany.
Purpose: Lutetium-177 Prostate-specific membrane antigen (Lu-PSMA) radioligand therapy is EMA-approved for metastatic castration resistant prostate cancer (mCRPC) after androgen receptor pathway inhibition (ARPI) and taxan-based chemotherapy. However, its effect in taxan-naïve patients is under current investigation.
Methods: We relied on the FRAMCAP database to elaborate Lu-PSMA therapy outcomes of progression-free (PFS) and overall (OS) in taxan-naïve mCRPC patients after previous ARPI treatment.
In this study, we present an unexplored approach for remote focus manipulation using 3D nanoprinted holograms integrated on the end face of multi-core single-mode fibers. This innovative method enables precise focus control within a monolithic metafiber device by allowing light coupled into any of the 37 cores to be precisely focused at predefined locations. Our approach demonstrates significant advances over conventional lenses and offers unique functionalities through computationally designed holograms.
View Article and Find Full Text PDFImpact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial.
Am J Gastroenterol
January 2025
Inflammatory Bowel Disease Center, Amsterdam University Medical Centers, Amsterdam, Netherlands.
Introduction: Patients with ulcerative colitis (UC) and prior biologic failure may have reduced or delayed efficacy with subsequent advanced therapies. This analysis evaluated the efficacy and safety of ozanimod during the True North (TN) study and its open-label extension (OLE) in biologic-exposed patients with UC.
Methods: TN was a randomized, placebo-controlled 52-week trial (10-week induction, 42-week maintenance period).
CAR T-cell-associated secondary malignancies challenge current pharmacovigilance concepts.
EMBO Mol Med
January 2025
Safety of Biomedicines and Diagnostics, Paul-Ehrlich-Institut, Langen, Germany.
Suspected adverse reactions following chimeric antigen receptor T-cell (CAR T) treatment include more and more cases of secondary T-cell malignancies. The causality assessment of such suspected reactions challenges established evaluation practices due to (i) patient and product-specific risk factors and (ii) incomplete data available with post-marketing reports submitted to competent authorities. This is of particular relevance for gene therapy products that integrate into the host genome.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!